相关实验视频
Updated: Jul 18, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.5K
帕金森病的亚thalamic核DBS的频率设置:一个系统的审查和网络元分析
Rajiv Dharnipragada1, Lalitha S Denduluri2, Anant Naik3
1University of Minnesota Medical School, University of Minnesota Twin-Cities, Minneapolis, MN, 55455, USA.
Parkinsonism & related disorders
|August 21, 2023
概括
在不对药物反应的帕金森病患者中,高频刺激 (HFS) 用于脑下核深度大脑刺激 (STN-DBS) 比低频刺激 (LFS) 更能改善运动症状. 当与药物相结合时,LFS显示有好处.
科学领域:
- 神经外科手术 神经外科手术
- 运动障碍 运动障碍
- 神经科学是一个神经科学.
背景情况:
- 深度脑刺激 (DBS) 是对帕金森病 (PD) 运动症状的关键治疗方法.
- 脑下细胞核 (STN) 领先位置是PD中DBS的标准.
- 通过统一帕金森病评级尺度III (UPDRS-III) 来衡量STN-DBS的有效性.
研究的目的:
- 为了比较STN-DBS中不同频率设置的有效性.
- 评估高频刺激 (HFS) 与低频刺激 (LFS) 的STN-DBS疗效.
主要方法:
- 一个PRISMA引导的随机对照试验系统审查和元分析.
- 提取的UPDRS-III结果和刺激参数 (HFS ≥100 Hz,LFS <100 Hz). 在此过程中,
- 使用Mantle-Haenszel方法进行频率主义网络元分析,以组合赔率比率.
主要成果:
- 分析了15项涉及298名患者的研究.
- 与双边LFS相比,双边HFS显示出更高的UPDRS-III分数.
- 药物治疗的双边LFS显示出比药物治疗的HFS更好的结果.
结论:
- 双边HFS对没有药物反应的帕金森病患者更有效.
- 当与药物一起使用时,LFS提供了附加的好处,针对不同的症状.
- 不同的神经生理机制是STN-DBS中HFS和LFS的基础.
相关概念视频
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Parkinson's Disease: Overview
596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596

